Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture
Private Company Edition: Westlake Village BioPartners launched with $320m and Harper as a managing director; UK-based Ahren unveiled a $100m-plus "deep science" fund; and UCSD partnered with Deerfield to finance drug programs. In new financings, Allogene leads with $120m.
You may also be interested in...
Finance Watch: Sana Reveals Cash Haul Of $700m In Under Two Years
Private Company Edition: The allogeneic cell therapy developer founded by former Juno execs launched in January 2019 without disclosing its initial funding. Other recent venture capital mega-rounds include $192m for Orca, $170m for C4, $118m for Shattuck and $102m for GreenLight.
Amgen’s R&D Group Focuses On Efficiency As Drug Cost Concerns Continue
Scrip spoke with R&D head David Reese about improving R&D timelines and success rates, including through the use of genomics and proteomics, as data readouts near for key drugs in big indications.
IPO Update: 35 Biopharmas Provide -6.1% Average Return; New Offerings Feel Stock Market Impact
Only 16 drug developers that went public in the US during the first three quarters are trading in positive territory. While the IPO queue keeps growing, ADC Therapeutics and Monopar cite "market conditions" as they postpone their offerings.